#Spain #Madrid #Asabys Partners #AltamarCAM Partners #Aliath Bioventures

Asabys Partners and AltamarCAM Partners: A Strategic Integration

In a significant move aimed at strengthening their position in the life sciences investment sector, Asabys Partners and AltamarCAM Partners have announced the integration of Aliath Bioventures into Asabys's framework. This collaboration not only signifies a melding of expertise and resources but is also a strategic alignment set to catalyze investment growth in Europe's healthcare landscape.

Founded in 2018, Asabys Partners has carved out a niche in the venture capital realm focusing on healthcare. With the recent integration, their assets under management will rise from €300 million to more than €400 million, opening new avenues for investments and creating synergies that benefit investors. The firms’ united commitment aims to raise their assets to over €1 billion by 2030, targeting crucial market segments including tech transfers, company births, and growth-stage investments.

Background of the Integration

The roots of this partnership lie in an existing collaborative history between the two firms, marked by successful co-investments in various companies such as Deepull, Ona Therapeutics, and Inbrain Neuroelectronics. Both Asabys and AltamarCAM share a vision focused on fostering innovation in healthcare, with an emphasis on scientific rigor and nurturing the next generation of healthcare innovators.

Josep Ll. Sanfeliu and Clara Campàs, co-founders of Asabys, expressed optimism regarding the acquisition, highlighting the wealth of experience the Aliath Bioventures team brings to the table. The integration is expected to enhance the operational capabilities of Asabys, enabling it to oversee a broader investment spectrum that nurtures startups from inception through to growth.

Future Prospects and Strategic Goals

As part of the newly formed alliance, the Alta Life Sciences Spain I FCR fund will be co-managed, facilitating a continuity of support for existing investments within the fund, which is performing well. Plans have been laid out to launch additional life sciences funds across various market segments in the coming years, aiming to solidify their position as a leading force in the European life sciences landscape.

The alignment comes at an opportune time when the healthcare investment sector is undergoing substantial transformation. Both firms are positioning themselves to leverage market consolidations, with an understanding that success will hinge on assembling top-tier technical teams and scaling resources effectively. This merger signifies more than just a growth in numbers but reflects a commitment to elevate the healthcare investment domain and maximize portfolio value.

As the landscape of healthcare investment continues to evolve, the partnership between Asabys Partners and AltamarCAM Partners sets a precedent for strategic collaborations aimed at maximizing investor value and enhancing support for healthcare innovators. With a robust investment strategy, the firms are on a trajectory to reshape the future of healthcare investment in Europe for years to come.

About Asabys Partners

Asabys Partners specializes in healthcare venture capital, focusing on disruptive innovations within the biopharmaceutical and health technology sectors. The firm boasts a diversified portfolio, having invested in 18 companies with two successful exits since its inception.

About AltamarCAM Partners

AltamarCAM is a global investment firm with a primary focus on providing institutional and high-net-worth investors with pathways to access private market investments. Operating in major financial hubs across the globe, it is well-equipped to capitalize on emerging opportunities within the life sciences sector and beyond.